期刊文献+

核苷(酸)类药与乙型肝炎病毒P基因变异特点及突变频率的关系

下载PDF
导出
摘要 目的观察核苷(酸)类药治疗不同时间段慢性HBV感染患者血清乙型肝炎病毒聚合酶(HBV P)基因序列变异特点及突变频率。方法以乙型肝炎病毒全序列为参照,针对P区目的位点,参考引物设计原则,运用焦磷酸测序仪器配套的软件Assay Design SW在目的区域两端保守区域设计PCR引物及测序引物,采用套式PCR方法检测血清中HBV DNA,按照PyroMark ID遗传分析系统用SNP模式进行PCR产物HBVP基因相关位点的焦磷酸测序、突变频率检测,同时测定患者血清HB-VDNA、HBVM、ALT。结果 34例患者中16例发生变异,变异模式以经典突变L180M、M204V/I、A181V/T、N236T突变为主,加少量V173L突变,发生变异者耐药突变型在样本中所占比例由20%到100%;HBVP基因变异可以在HBVDNA、ALT发生突破前、中、后检出;发生HBeAg转化者P基因变异率较低。结论焦磷酸测序可以快速、准确的检测出HBVP基因变异;HBVP基因变异模式、突变频率与核苷类药物敏感性密切相关。
出处 《齐齐哈尔医学院学报》 2012年第7期871-872,共2页 Journal of Qiqihar Medical University
基金 南通市科委课题(编号S9923)
  • 相关文献

参考文献5

二级参考文献12

  • 1Orlando R, Tosone G, Portella G, et al. Prolonged persistence of lamivudine-resistant mutant and emergence of new lamivudine-resistant mutants two years after lamivudine withdrawal in HBsAg-positive chronic hepatitis patient: a case report. Infection, 2008, 36: 472-474.
  • 2Ono SK, Kato N, Shiratori Y, et al. The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance. J Clin Invest, 2001, 107: 449-455.
  • 3Villet S, Pichoud C, Billioud G, et al. Impact of hepatitis B virus rtA181V/T mutants on hepatitis B treatment failure. J Hepatol, 2008, 48: 747-755.
  • 4Tenney D J, Levine SM, Rose RE, et al. Clinical emergence of entecavir-resistant hepatitis B virus requires additional substitutions in virus already resistant to Lamivudine. Antimicrob Agents Chemother, 2004, 48: 3498-3507.
  • 5Ijaz S, Arnold C, Dervisevic S, et al. Dynamics of lamivudine-resistant hepatitis B virus during adefovir monotherapy versus lamivudine plus adefovir combination therapy. J Med Virol, 2008, 80:1160- 1170.
  • 6Lee YS, Suh DJ, Lim YS, et al. Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. Hepatology, 2006, 43: 1385-1391.
  • 7Gerolami R, Bourliere M, Colson P, et al. Unusual selection of rtA181V HBV mutants cross-resistant to adefovir following prolonged lamivudine monotherapy: report of two cases. Antivir Ther, 2006, 11: 1103-1106.
  • 8Zhang X, Liu C, Gong Q, et al. Evolution of wild type and mutants of the YMDD motif of hepatitis B virus polymerase during lamivudine therapy. J Gastroenterol Hepatol, 2003, 18: 1353-1357.
  • 9Ciancio A, Smedile A, Rizzetto M, et al. Identification of HBV DNA sequences that are predictive of response to lamivudine therapy. Hepatology, 2004, 39: 64-73.
  • 10Stephan C, Berger A, Carlebach A, et al. Impact of tenofovir-containing antiretroviral therapy on chronic hepatitis B in a cohort coinfected with human immunodeficiency virus. J Antimicrob Chemother, 2005, 56: 1087-1093.

共引文献20

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部